Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials

Table 2 Treatment-emergent adverse events (TEAE) occurring in at least 5% of patients who received duloxetine

	Older		Younger
	Placebo N=94 n (%)	Duloxetine N=103 n (%)	Placebo N=154 n (%)	Duloxetine N=136 n (%)	Treatment-by-Age Group Interaction p values
Patients with at least one TEAE	40(42.6)	55(53.4)	51 (33.1)	65(47.8)	.66^a
Constipation	2 (2.1)	11 (10.7)	0 (0)	3 (2.2)	1.00^b
Diarrhea	2 (2.1)	4 (3.9)	4 (2.6)	7 (5.1)	.93
Dizziness	3 (3.2)	1 (1.0)	1 (0.6)	9 (6.6)	.02
Nausea	3 (3.2)	9 (8.7)	2 (1.3)	11 (8.1)	.40^c
Somnolence	3 (3.2)	6 (5.8)	1 (0.6)	4 (2.9)	.49
Patients with at least one SAE	2 (2.1)	3 (2.9)	2 (1.3)	1 (0.7)	.57

^a treatment effect, p=.005.
^b treatment effect, p=.03.
^c treatment effect, p=.004.
Abbreviations: TEAE, treatment-emergent adverse event; SAE, serious adverse event.

ISSN: 1471-2474